Transcendental Meditation (TM) to reduce stress and improve immunity of health care providers during COVID-19 pandemic

Transcendental Meditation (TM) to redUce stRess and enhance iMmunity of hEalth care woRkers during COVID-19 pandemiC: A randomized trial - TURMERIC trial

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/027910

Enrollment

Registered

2020-09-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Transcendental Meditation (TM): The participating Health Care providers including doctors, nurses, and other healthcare staff involved in COVID-19 patient care will be randomized into t

Eligibility

Inclusion criteria

Inclusion criteria: 1. Any healthcare provider including doctors, nurses, and other healthcare staff involved in COVID-19 patient care at All India Institute of Medical Sciences is eligible for the study. 2. Agreement to attending the 5-day session for learning TM and dedicating 40 mins per day for practice TM at home/workplace

Exclusion criteria

Exclusion criteria: 1. Healthcare provider with a history of autoimmune disorders/compromised immunity/trauma related issues/complicated diabetes/renal disorders/etc. 2. Those with any form of recreational drug use within the past 15 days from learning TM, are not eligible to learn TM and thus will be excluded from this study or will be taught at a later time. 3. Any individual who has learnt TM in the past. 4. Any individual currently practicing any other form of meditation.

Design outcomes

Primary

Measure	Time frame
Perceived stress, measured using Perceived stress scale (PSS)Timepoint: Baseline and at one, two and three months post intervention	—

Secondary

Measure	Time frame
Immune cell counts: CD3 will be used to identify T-cells, CD4 for helper T-cells, CD8 for cytotoxic T-cells, CD20 for B-cells, CD16 and CD56 for natural killer (NK) cells. Plasma cells expression will also be evaluated Timepoint: Baseline and at one and three months post intervention;Inflammatory Cytokines (Il-6,8,10, and tumor necrosis factor (TNF)-Î±Timepoint: Baseline and at one and three months post intrvention;Salivary cortisol and salivary amylase, Serum Cortisol and Beta-Endorphins levels.Timepoint: Baseline and at one and three months post intervention;Self-perceived immune status Health related quality of life will be assessed by Short Form-36 Timepoint: Baseline and at one, two and three months post intervention	—

Measure

Time frame

Immune cell counts: CD3 will be used to identify T-cells, CD4 for helper T-cells, CD8 for cytotoxic T-cells, CD20 for B-cells, CD16 and CD56 for natural killer (NK) cells. Plasma cells expression will also be evaluated Timepoint: Baseline and at one and three months post intervention;Inflammatory Cytokines (Il-6,8,10, and tumor necrosis factor (TNF)-Î±Timepoint: Baseline and at one and three months post intrvention;Salivary cortisol and salivary amylase, Serum Cortisol and Beta-Endorphins levels.Timepoint: Baseline and at one and three months post intervention;Self-perceived immune status Health related quality of life will be assessed by Short Form-36 Timepoint: Baseline and at one, two and three months post intervention

—

Countries

India

Contacts

Public ContactRini Vohra

All India Institute of Medical Sciences (AIIMS), New Delhi

dr_hkb75@yahoo.com7838621462

Outcome results